Online inquiry

IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13521MR)

This product GTTS-WQ13521MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13521MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2461MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ14853MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ381MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ10714MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ14889MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ910MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ9658MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ11505MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MetMAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW